Protalix Biotherapeutics Drops After FDA Extends Taliglucerase Alfa PDUFA Date | Daily Herald

Home Delivery Order Customer Service

Latest Area News & Weather

More Headlines Find your community Weather Forecast

Digital Subscriptions Learn more

Showing
ALL
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Select a community above or click here to close

Photos Video

Send your News, Photos and Events

Facebook Twitter RSS LinkedIn YouTube

Protalix Biotherapeutics Drops After FDA Extends Taliglucerase Alfa PDUFA Date

By: home: iStockAnalyst.com Feed

Posted on December 06, 2011 at 10:08 AM EST

Protalix BioTherapeutics Inc. (NYSEAMEX:PLX) said the Prescription Drug User Fee Act (PDUFA) goal date of the New Drug Application (NDA) for its enzyme replacement therapy to treat Gaucher disease has been extended by three months by the U.S. health regulators to May 1, 2012. [More...]

Related Stocks:

Protalix BioTherapeutics, Inc.

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates

SiteIndex

CommunityFinder